Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.36), $0.02 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $8.12 million versus the consensus estimate of $10.22 million.

Cash and cash equivalents and marketable securities as of September 30, 2021 were $249.6 million, compared to $177.0 million as of December 31, 2020. As of September 30, 2021, there were 41,412,875 common shares, 1,081,081 pre-funded warrants and 1,016,000 Series 1 Preferred Shares, which are convertible into common shares on a one-for-one basis at the option of the holder, subject to certain limitations.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.